A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Clinical trial NCT05280275 · UNKNOWN

Trial details

NCT number: NCT05280275
Sponsor: Hellenic Society of Hematology
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma Neoplasms Neoplasms, Plasma Cell Gammopathy, Monoclonal Paraproteinemias Blood Protein Disorders Haematologic Disease Corneal Disease

Start date: 2022-04-13
Primary completion: 2026-03-15
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.